Skip to main content

DIPHERELINE (Ipsen Pty Ltd)

Product name
DIPHERELINE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
206 (175 working days)
Active ingredients
triptorelin embonate
Registration type
EOI
Indication

DIPHERELINE 22.5mg (powder for suspension vial and water for injections ampoule) 6 month formulation only.

DIPHERELINE 22.5 mg is now also indicated for the treatment of children 2 years and older with central precocious puberty (CPP).

Help us improve the Therapeutic Goods Administration site